High-Risk Populations for Severe Pneumococcal Infection

Author(s):

Christina M. Madison, PharmD, FCCP, AAHIVP,Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP

Key opinion leaders identify high-risk populations for invasive pneumococcal disease, explain the underlying factors contributing to their increased susceptibility, and offer strategies to improve suboptimal vaccination rates, particularly among historically underserved communities.

EP: 1.Symptomatology and Transmission of Pneumococcal Infection

EP: 2.Manifestation of Pneumococcal Disease in Adults

Now Viewing

EP: 3.High-Risk Populations for Severe Pneumococcal Infection

EP: 4.Patient Burden Associated with Pneumococcal Disease

EP: 5.Vaccination Efforts to Mitigate Pneumococcal Outbreaks

EP: 6.Comparing and Contrasting the Characteristics of the FDA-Approved Pneumococcal Vaccines

EP: 7.Target Patient Populations for Pneumococcal Vaccines

EP: 8.ACIP Recommendations for Pneumococcal Vaccination

EP: 9.Clinical Considerations for Pneumococcal Vaccination Scheduling

EP: 10.Clinical Data Supporting Pneumococcal Vaccination

EP: 11.Insights on Conjugate Pneumococcal Vaccines

EP: 12.Future Considerations for Pneumococcal Vaccination

EP: 13.Barriers to Administering Pneumococcal Vaccines and Best Practices for Overcoming Them

EP: 14.Optimizing Pneumococcal Vaccination Efforts in High-Risk Patients

EP: 15.Closing Thoughts From The Panel On Pneumococcal Vaccination

Who are the high-risk populations for developing invasive pneumococcal disease?
1. What is the rationale for why certain populations are at risk for severe pneumococcal infections?
2. How can we improve inadequate pneumococcal vaccine uptake rates, specifically in historically marginalized groups?

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!